Valion Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $3.92M
- P/E (TTM)
- –
- Dividend yield
- –
About Valion Bio
Pharmaceutical Preparations, SIC 2834
Tivic Health Systems, Inc. operates within the health technology and biopharmaceutical sectors. The company identifies business activities across Biopharma and contract development and manufacturing organization (CDMO) segments, while classifying its Clearup operations within discontinued operations. Through licensing agreements, it engages in biopharmaceutical drug development, including milestones for acute radiation syndrome therapies and neutropenia applications, alongside CDMO-related services.
The company maintains its principal executive offices in San Antonio, Texas, with additional historical facility lease commitments and operations cited in Hayward, California. Its corporate infrastructure and commercial development activities also reference leases for mammalian, microbial, and office facilities. Its common shares trade publicly on the Nasdaq Stock Market.
Summary of the business section of Valion Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Valion Bio, Inc.
- Headquarters
- San Antonio, TX
- Address
- 1305 E. Houston Street, Building 1, Suite 311 78205
- Phone
- (888) 276-6888
- Website
- valionbio.com
- Employees
- 52, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey
Stock & identifiers
- Ticker
- VBIO
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2021
- Shares outstanding
- 22M, Aug 13, 2026
- Public float
- $4.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Aug 31, 2026; 1-for-17 reverse, Mar 7, 2025; 1-for-17 reverse, Mar 7, 2025; 1-for-100 reverse, Aug 23, 2023; 1-for-100 reverse, Aug 23, 2023
- SEC CIK
- 1787740
- CUSIP
- 918942202
- ISIN
- US9189422028
- EIN
- 81-4016391
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dean Zikria | Interim CEO, Director | – |
| Michael K. Handley | Chief Executive Officer, Director | 11,030 |
| Jennifer Ernst | Chief Executive Officer, Director | 37,953 |
| Lisa G. Wolf | COO & CFO | 27 |
| Melinda Lackey | General Counsel & SVP of Legal | – |
| Blake Gurfein | Chief Scientific Officer | 119,979 |
| Jared David Malbin | Director | – |
| Thomas Jensen | Director | – |
| Sheryle Bolton | Director | 10,000 |
| Christina Rizopoulos Valauri | Director | 19,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 52 full-time employees.”
Corporate history
Events identified from SEC filings